Q3 EARNINGS: Qiagen facing HPV headwinds; Lombard, SnN, Teleflex
This article was originally published in Clinica
Dutch molecular diagnostics specialist Qiagen posted an in-line third quarter, with sales of $336.8m and adjusted earnings of $0.27 per share bang on analyst consensus. However, the firm is facing a challenging human papillomavirus (HPV) testing market, where it has been forced to cut its prices due to competition. “US HPV [sales] declined faster than expected and should continue to be a drag on top-line growth in 2015,” wrote Goldman Sachs analyst Isaac Ro. “However, [the franchise] is now small enough as a percentage of total sales to be offset by other growth opportunities.”
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.